Target intelligence / Profile preview

Enterovirus C viral capsid

Molecular classification
Viral capsid protein complex, Structural protein complex, Other
01

Overview

The **Enterovirus C viral capsid** is a protein shell enclosing the single-stranded positive-sense RNA genome of Enterovirus C species, which encompasses polioviruses and several coxsackieviruses. The capsid adopts an icosahedral symmetry, composed of 60 protomers; each protomer is made up of four structural proteins: VP1, VP2, VP3 (all surface-exposed), and VP4 (internal). The major surface-exposed VP1 forms the 'canyon' and contains a hydrophobic 'pocket factor' site that is critical for capsid stability and the process of viral uncoating during infection[1][3]. Key features of the capsid, such as the antigenic loops of VP1, are targets for neutralizing antibodies and small-molecule inhibitors. The capsid is central to disease progression as it enables both persistence in harsh extracellular environments and the recognition and entry into susceptible host cells by interacting with specific cellular receptors. Variability in capsid proteins underlies serotype diversity, immune escape, and impacts the effectiveness of potential capsid-targeting antivirals or vaccines[1][3][9].

Other names
Enterovirus C capsidPoliovirus capsid (for poliovirus strains in Enterovirus C)Coxsackievirus A capsid (for Coxsackie A viral strains in Enterovirus C)EV-C capsid
02

Mechanism of action

Inhibitor binds to the hydrophobic “pocket factor” site in capsid (notably in the VP1 subunit), stabilizing the capsid, thus preventing “pocket factor” expulsion and subsequent uncoating/genome release necessary for infection[1][9]. Antibody-mediated neutralization, especially against external capsid loops and N-terminal region of VP1, blocking receptor binding or triggering uncoating[3].

03

Biological functions

Encapsulation of viral RNAProtection of viral genomeMediation of host cell entryAntigenic structure for immune recognition
04

Disease associations

Infection
05

Safety considerations

Development of drug resistance due to high mutation rates in viral capsid genesPotential for immune escape variants (antigenic variation in capsid loops)Limited cross-neutralization between different serotypes
06

Interacting drugs

WIN 51711 (capsid-binding inhibitor)

2 more in the full profile.

07

Biomarkers

Capsid protein-specific antibodies (e.g. neutralizing antibodies against VP1, used in serological diagnostics and monitoring vaccine response)[3]Presence of viral capsid antigens in patient biosamples (infection biomarker)

Beyond the preview

Go deeper on Enterovirus C viral capsid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enterovirus C viral capsid.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call